⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Die frühere Anwendung von CARVYKTI®▼ (ciltacabtagene autoleucel) führte bei Patienten mit rezidiviertem oder refraktärem Multiplem Myelom nach 2,5 Jahren zu einer anhaltenden, behandlungsfreien Remission
globenewswire.com
JNJ
LGND
MIKEWORLDWIDE APPOINTS ABRAHAM ESPINOSA AS EXECUTIVE VICE PRESIDENT OF STRATEGY
prnewswire.com
JNJ
PEP
VZ
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
prnewswire.com
JNJ
Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
globenewswire.com
JNJ
LGND
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
prnewswire.com
JNJ
K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief
prnewswire.com
SWX
JNJ
BMY
Immunotherapy Drugs Research Report 2025: $526.5 Bn Market Opportunities, Growth Drivers, Industry Trend Analysis, and Forecast 2024-2034
globenewswire.com
AMGN
PFE
JNJ
BMY
GILD
MRK
MDT
ADAP
Companion Diagnostics Market Research 2025: $21+ Bn Opportunities, Growth Drivers, Industry Trend Analysis, and Forecasts 2024-2034
globenewswire.com
PFE
MRK
AZN
TMO
ABT
AMGN
JNJ
BMY
LLY
MYGN
GRDX
BIIB
BDX
U.S. Flexible Endoscopic Surgery Robot Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034
globenewswire.com
ISRG
JNJ
MDT
Rising Stars in Cardiac Electrophysiology: ABC Announces 2026-2027 Fellowship Recipients
prnewswire.com
JNJ